ALNY - Alnylam Pharmaceuticals Inc. Looks to Continue to Trade Above its Annual-High Share Price Today

Shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded at a new 52-week high today of $203.31. So far today approximately 118,000 shares have been exchanged, as compared to an average 30-day volume of 678,000 shares.

Over the past year, Alnylam Pharmaceuticals Inc. has traded in a range of $119.29 to $203.31 and is now at $200.74, 68% above that low.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is currently priced 2.0% above its average consensus analyst price target of $196.68.

Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer